ROIV Stock Summary and Trading Ideas (Roivant Sciences Ltd. - Common Shares | NASDAQ:ROIV)

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Roivant Sciences Ltd. - Common Shares trades on the NASDAQ stock market under the symbol ROIV.

As of January 3, 2025, ROIV stock price declined to $11.69 with 3,190,103 million shares trading.

ROIV has a beta of 0.68, meaning it tends to be less sensitive to market movements. ROIV has a correlation of 0.07 to the broad based SPY ETF.

ROIV has a market cap of $8.51 billion. This is considered a Mid Cap stock.

In the last 3 years, ROIV traded as high as $13.24 and as low as $2.52.

The top ETF exchange traded funds that ROIV belongs to (by Net Assets): VTI, IJH, VB, XBI, VXF.

ROIV has underperformed the market in the last year with a return of +7.6%, while the SPY ETF gained +27.8%. In the last 3 month period, ROIV fell short of the market, returning +4.3%, while SPY returned +4.6%. However, in the most recent 2 weeks ROIV has outperformed the stock market by returning +1.0%, while SPY returned +0.1%.

ROIV support price is $11.86 and resistance is $12.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ROIV shares will trade within this expected range on the day.